

Supplemental Materials for The OncoSim-Breast Cancer Microsimulation model

J.H.E. Yong MASc, C. Nadeau PhD, W. Flanagan BM, A. Coldman PhD, K. Asakawa PhD, R. Garner PhD, N. Fitzgerald MA, M. Yaffe PhD, A.B. Miller MD on behalf of the OncoSim-Breast Working Group

Listing of Supplemental Material(s):

Supplemental Appendix 1: Demography

Supplemental Appendix 2: Natural history

Supplemental Appendix 3: Cancer detection, staging and tumour biology

Supplemental Appendix 4: Screening

Supplemental Appendix 5: Disease progression

Supplemental Appendix 6: Breast cancer healthcare costs

Supplemental Appendix 7: Quality-adjusted life-years

Supplemental Appendix 8: OncoSim-Breast Working Group

Supplemental Appendix 1: Demography

OncoSim simulates birth in 1872-2051 according to the Canadian demographics: population size of each province/territory and sex distribution; the model uses actual population counts up to 2006 and projections from the Demography division for 2007 and beyond. All-cause mortality came from Canadian life tables and is affected by smoking (the model simulates smoking history for each individual). Average health-related quality of life of the general population varies by age and sex.

Risk factors

We included key risk factors for oncogenesis and tumour growth: BRCA1/2 gene mutation, family history of breast cancer, and exposure to hormone replacement therapy (HRT).

Family history of breast cancer and BRCA1/2 gene mutation: Women are assigned to one of four categories; the distribution is an input parameter (Supplemental Table 1).

Supplemental Table 1. Family history and BRCA1/2 gene mutation distribution

BRCA1/2 gene mutation	Family history	% of women^a
BRCA1 and/or 2	All	0.1
No mutation	First-degree family history of breast cancer	10.0
No mutation	Second-degree family history of breast cancer	15.0
No mutation	No family history	74.9

^a Proportion of women with BRCA1/2 gene mutation came the Anglian Breast Cancer Study group, 2000; family history distribution was estimated from the Canadian National Breast Screening Study (CNBSS).¹ In that screening trial, ~27% of women aged 40-49 recruited to the trial had second-degree relative who had breast cancer.¹ We think that the 27% prevalence is likely an overestimate because women with family history of breast cancer may have been more likely to self-refer to the screening trial.

Hormone replacement therapy use: Combination HRT use was modeled using data from the longitudinal National Population Health Survey (1994-2010). The use of combination HRT started in 1990, and varied by age, time period and geography. In OncoSim, current and former use of combination HRT affects the risk of developing breast tumour and the sensitivity of mammography screening.

Supplemental Appendix 2: Natural history

The natural history of breast cancer is a process of occult tumour onset (oncogenesis), growth and spread. Tumours may be detected clinically as a result of physical symptoms, or asymptotically as a result of screening. Tumour detection provides insight into the natural history process by identifying characteristics of tumours such as size, nodal status, and metastatic status according to age at detection.

OncoSim-Breast simulates ductal carcinoma *in situ* (DCIS) and invasive cancer: it does not simulate other types of *in situ* tumours (e.g. lobular carcinoma *in situ*) or other precursor tumours. Over the course of a simulated woman's lifetime, she may develop:

- a single DCIS tumour;
- a single invasive tumour;
- a single DCIS tumour that becomes invasive; or
- no breast tumour at all.

Ductal carcinoma *in situ* (DCIS) is treated as a marker of risk of invasive breast cancer, thus the presence of DCIS will modify the risk of developing invasive breast cancer, this allows for invasive cancer to occur in the absence (or presence) of DCIS.


Occult tumour onset

This equation describes the tumour onset (oncogenesis) in OncoSim:

$$\text{Oncogenesis rate} = \text{Baseline}(\text{age, year}) * \text{RR}_{\text{PREDISPOSITION}} * \text{RR}_{\text{HRT}} + \text{AR}_{\text{PREVIOUS}}$$

The *Baseline* term represents the assumed hazard of developing an occult tumour by age and year for all women in the population (Supplemental Figure 1). Baseline rates are adjusted according to a woman's predisposition category ($\text{RR}_{\text{PREDISPOSITION}}$), her use of HRT (RR_{HRT}) and if she has previously had a tumour ($\text{AR}_{\text{PREVIOUS}}$). Since we only simulate one of each tumour type in this version of the natural history model, this last term is only applied for women who have previously had a DCIS tumour as an increased risk of developing an invasive cancer.

The most common way for an invasive cancer to be “born” is from a prior DCIS tumour. However, an invasive tumour can be born without an explicit *in situ* phase – these tumours may be seen/construed as having an *in-situ* phase that became invasive prior to reaching the 2mm threshold of the simulation and therefore escape expression in the model. Additionally, because OncoSim-Breast does not explicitly model *in situ* breast cancer other than DCIS, in cases where natural history models invasive breast cancer without a prior DCIS, these could conceptually arise out of other *in situ* tumours that are not DCIS. In OncoSim, the incidence varies by age group and time period. It was calibrated from the inputs in the Wisconsin Breast model to match the incidence data in the National Cancer Incidence Reporting System (1969-1991) and the Canadian Cancer Registry (1992-2013) (Supplemental Figure 1). After a tumour is simulated, the model assigns the tumour type (DCIS vs. invasive) by age (Supplemental Table 2).



Supplemental Figure 1. Incidence of 2mm occult tumours by age and time period (baseline)

Supplemental Table 2. Distribution of tumour type by age

Age	0-54	55-64	65-69	70-79	80+
DCIS	19%	10%	16%	11%	2%
invasive	81%	90%	84%	89%	98%

Source: Calibration

Impact of family history and BRCA1/2 gene mutation on incidence: Women with BRCA1 and/or 2 gene mutation or family history of breast cancer have higher risk of breast cancer than those without the gene mutation nor family history (Supplemental Table 3).

Supplemental Table 3. Impact of family history and BRCA1/2 gene mutation on breast cancer incidence

BRCA1/2 gene mutation	Family history	Relative risk ^a Mean (variance)
BRCA1 and/or BRCA2 gene mutation	All	9.67 (0)
No mutation	First-degree family history of breast cancer	1.88 (4.2)
No mutation	Second-degree family history of breast cancer	1.41 (4.2)
No mutation	No family history	0.94 (4.2)

^a Relative risk of developing occult tumour, as compared to average risk women, was modelled with a gamma distribution; the parameters (1.88 and 1.41) were calibrated from published estimates.²

Hormone replacement therapy use: In OncoSim, current and former use of combination HRT increases the risk of developing breast tumour (Supplemental Table 4).

Supplemental Table 4. Relative risk of developing breast cancer among HRT users, as compared to non-users.

Current users by duration use (years):	Relative risk^a
0 to 2	1.3
2 to 4	1.8
4 or more	2.2
Former users by time since quitting (years)	
0 to 20	1.5
20 or more	1.0

^a Relative risk of developing breast cancer was calibrated to match results of a study reporting impact of HRT on breast cancer risk.³

Tumour growth


Tumours grow according to years since tumour onset, the presence of BRCA1/2 gene mutation, tumour type (DCIS or invasive) and tumour growth aggressiveness (non-aggressive or aggressive) (Supplemental Figure 2). All tumours were assumed to grow according to a Gompertz distribution that gives the tumour diameter (d) in cm as a function of years since tumour onset (t), scaled according to the maximum diameter allowed for the particular tumour type, according to the equation:

$$d(t) = d_0 \left(\frac{d_{\max}}{d_0} \right)^{\left(1 - \exp(-\alpha t) \right)}$$

where

- d_0 is the diameter of the tumour at occult onset (0.2cm)
- d_{\max} is the maximum size the tumour is allowed to reach
- α represents the tumour growth rate estimated through model fitting.
- t represents the years since tumour onset

The growth curves were calibrated from the Wisconsin Breast model's parameters to match stage-specific incidence data in Canadian Cancer Registry (1992-2013) and Canadian Breast Cancer Screening Database (2007-2008) and various other targets. The breast tumour growth equation coefficients are listed in Supplemental Table 5.



Supplemental Figure 2. Tumour growth curves (mean growth rate and mean max size by tumour type, class and age)

Supplemental Table 5. Breast tumour growth equation coefficients

BRCA1/2	Tumour type	Tumour class (% split within tumour type) ^a	Growth Rate, α		Maximum diameter (cm), d_{max}	
			Mean	Variance	Mean	Variance
BRCA1/2	DCIS & invasive		1.36	1.73	7.75	0.00
Non-BRCA1/2	DCIS	Non-aggressive (96%)	0.43	3.48	2.54	2.62
		Aggressive (4%)	1.60	2.30	3.78	4.54
	Invasive	Non-aggressive (92%)	1.36	1.73	2.91	1.50
		Aggressive (8%)	2.23	0.71	9.01	0.90

^a Distribution of tumour class (aggressive vs. non-aggressive) was estimated through calibration.

Tumour spread

Number of lymph nodes affected: Invasive tumour can spread into lymph nodes. The spread (number of positive nodes) is determined by size and growth rate of the tumour, and years since tumour onset.

$$\lambda(t) = \mu_N \{b_1 + b_2 V(t) + b_3 V'(t)\}$$

where

- μ_N is a random term drawn at time of tumour onset that allows for heterogeneity of tumours to generate positive nodes (Supplemental Table 6);
- b_1, b_2, b_3 are coefficients estimated through calibration of natural history;
- $V(t)$ denotes the volume of the spherical tumour;
- $V'(t)$ denotes the growth rate of the volume, and is the derivative of $V(t)$;
- t represents the age of the tumour, i.e., years since oncogenesis.

The equation was developed from the CISNET-Wisconsin model, and calibrated to match positive node data in Canadian Cancer Registry (1992-2013) and Canadian Breast Cancer Screening Database (2007-2008).

Metastasis: Hazard of metastasis, cancer spreading to places beyond the breast, depends on the tumour size and number of positive nodes (N^*).

Hazard of metastasis = $\mu_M \cdot k(\text{tumour size, number of positive nodes})$

where

- μ_M is a random term drawn at time of tumour onset that allows for heterogeneity (Supplemental Table 6);
- k is an annual hazard rate estimated through model calibration. It is a function of tumour size and number of positive nodes.

The hazard was calibrated to match stage-specific incidence data in Canadian Cancer Registry (1992-2013) and Canadian Breast Cancer Screening Database (2007-2008).

Supplemental Table 6. Random terms to generate number of positive nodes and metastasis status

BRCA1/2	Tumour class	μ_N	μ_M
BRCA1/2	All	0	0
Non-BRCA1/2	Non-aggressive	(1.2, 2.2)	(0.2, 0.2)
	Aggressive	(3.0, 0.1)	(0.02, 0.02)

Supplemental Appendix 3: Cancer detection, staging and tumour biology

Clinical detection

Tumour size determines the probability of tumour getting clinically detected (Supplemental Table 7). Clinical detection probability was calibrated from the inputs in the Wisconsin Breast model to match the incidence data in the National Cancer Incidence Reporting System (1969-1991) and the Canadian Cancer Registry (1992-2013). The hazards were interpolated linearly for in-between sizes.

Supplemental Table 7. Annual probability of clinical detection by tumour size

Tumour size (cm)	0.2	0.3	0.9	1.4	1.9	2.8	3.7	4.7	7.5	8.4
Probability of tumour getting detected clinically, per year	0.7 %	0.7 %	7%	8%	30%	55%	75%	80%	100 %	100 %

Stage at detection

Once tumour has been detected, stage is assigned based on tumour size (T), nodal status (N), and metastasis (M), according to the American Joint Committee on Cancer (AJCC)'s version 7 classification.

T: The model assigns T (in TNM) at the time of detection. First, it takes a random draw to determine whether it is a T4 tumour. Probability of a T4 tumour (have extended to the chest and/or skin) is a function of age, tumour size T^* , number of nodes N^* and metastatic status M . Next, it estimates T based on T^* (e.g. $2\text{cm} < T^* < 5\text{cm} \rightarrow T=T2$) for non-T4 tumours.

N: The model assigns nodal status (N in TNM) at the time of detection from a distribution that depends on age, N^* , and T, fitted using the Canadian Cancer Registry data.

Breast tumour biology

To simplify the model, OncoSim assigns tumour biology (hormone receptor status, HER2neu status, and grade) once tumour has been detected. The distribution of these biological factors was estimated from the Canadian Cancer Registry by tumour size (Tis, T1a, T1b, T1c, T2, T3, T4), nodal involvement (N0, N1, N1mi, N2, N3), metastatic status and age of woman at tumour detection (10-year age groups). Women with BRCA1/2 gene mutation has different distribution of tumour biology than women without BRCA1/2 gene mutation⁹. For women who used hormone replacement therapy, we adjusted tumour grade accordingly.¹⁰


Supplemental Appendix 4: Screening

In Canada, breast cancer screening started in the early to mid 1980s. The model assumed that screening started in 1986. In the screening module, user can create screening scenarios by specifying the characteristics of screening strategies:

- Screening modality
- Sensitivity and specificity of screening
- Screening participation and retention
- Screening frequency, target population and start/end years
- Costs of screening and follow-up procedures

Impact of screening on survival


In OncoSim, screening can detect tumours earlier than they would have been detected clinically. The survival from time of screen-detection to breast cancer death includes lead time and net survival benefit (Supplemental Figure 3). We calibrated lead time to match the observed survival data in a cohort of women diagnosed with breast cancer in British Columbia in 2006-2009; the survival data from these women were available up to 2014. Screen detection also leads to a stage shift that contributes to the survival benefit. The model reports overdiagnosis (cancers that would not otherwise present clinically) as an output.



Supplemental Figure 3. Illustration to show how screening affects survival

Screening modality


The model allows screening modality to vary by province and time period. In the base case scenario, we assumed that all provinces use digital radiography mammography in 2018 and beyond. The model also includes emerging screening modalities, such as tomosynthesis and ultrasound, to accommodate changes in screening modality in the future. To evaluate a new screening modality, users can change the distribution of screening modality and test performance. The historical screening test distribution for each province came from the Canadian Breast Cancer Screening Database (Supplemental Figure 4).



Supplemental Figure 4. Historical mammography distribution by province and year

Sensitivity

Sensitivity of screening test varies by time period, type of mammography, screen sequence, age group and tumour size (Supplemental Figure 5). The sensitivity estimates were calibrated from the inputs in the Wisconsin Breast model to match the incidence data in the National Cancer Incidence Reporting System (1969-1991) and the Canadian Cancer Registry (1992-2013), positive predictive value, sensitivity and tumour detection rate in the Canadian Breast Cancer Screening Database (CBCSD) in 2007-2008.



Supplemental Figure 5. Sensitivity of mammography in 2010, by age group, tumour diameter cut-points, type of mammography, and screen sequence

Specificity

The model allows users to set specificity of screening test by screen sequence, time since previous screen, age group, time period, screening modality and breast density. In the base case scenario, specificity of screening test varies by screen sequence and age (Supplemental Table 8), but not by modality and breast density.

Supplemental Table 8. Specificity of mammography screening by screen sequence and age

Screen sequence	Time since previous screen	Age group				
		Under 40	40-49	50-59	60-69	70+
First screen	-	0.856	0.856	0.876	0.894	0.916
Subsequent screen	< 30 months	0.937	0.937	0.945	0.952	0.956
	> 30 months	0.912	0.912	0.919	0.926	0.930

Source: Calibration started with estimates from Coldman et al. to match the 2008 abnormal call rate reported in the Canadian Breast Cancer Screening Database.¹¹

Impact of HRT use on Sensitivity and Specificity

Sensitivity is reduced by 15% for women aged 70 or older actively taking combination HRT. Specificity is reduced by 0.5% for women aged 50-59 actively taking combination HRT, by 2.5% for women aged 60-69 actively taking combination HRT, and by 3.5% in women aged 70 and older actively taking combination HRT. These estimates were based on Carney et al. (2003).¹²

Costs of screening and workup

The base case scenario assumed each screening mammogram costs \$64.15, which includes the technical and professional components of physician fees for performing a bilateral mammogram for asymptomatic individuals.¹³ We assumed all abnormal findings are followed-up with diagnostic imaging. Supplemental Table 9 shows the weighted cost of workup (imaging, core biopsy, fine-needle aspiration and open biopsy). The costs were estimated using abnormal workup distribution data from the Ontario Breast Screening Program and the technical and professional components of physician fees for performing the workup.^{13,14}

Supplemental Table 9. Distribution and weighted cost of follow-up workup for women with abnormal mammogram results

Diagnostic procedures	Weighted cost^a	False positive	True positive
Imaging only^b	\$68.32	91.1%	0
Imaging + core biopsy and/or fine needle aspiration^c	\$181.42	7.7%	89.3%
Imaging + open biopsy^d	\$431.88	1.2%	10.7%
Weighted cost		\$81.56	\$208.23

^aOHIP physician fees¹³


^b18.6% receive mammogram only, 22.1% receive ultrasound only, 58.4% receive mammogram and ultrasound, 0.9% receive mammogram, ultrasound and magnetic resonance imaging (MRI), estimated from Canadian Breast Cancer Screening Database 2004-2008.

^c83.6% receive core biopsy only, 16.4% receive core biopsy and fine needle aspiration, estimated from Canadian Breast Cancer Screening Database 2004-2008.

^d75.4% receive open biopsy with fine wire localization, estimated from Canadian Breast Cancer Screening Database 2004-2008.

Supplemental Appendix 5: Disease progression

Upon cancer detection, the model draws time to disease progression (recurrence and breast cancer death), based on stage, tumour biology, age at diagnosis, and detection method (clinically or screening). A woman will die from breast cancer if the simulated time to breast cancer death is sooner than the simulated time to non-breast cancer death. We modeled disease progression using data from a cohort of women diagnosed with breast cancer in British Columbia between 2006 and 2009 and followed up until 2014. We fitted the stage-specific outcomes data (diagnosis to local recurrence, diagnosis to distant recurrence, local recurrence to distant recurrence, etc.) to Weibull regression models, controlling for number of years from diagnosis, age, grade, hormone status, her2-neu status, screening status, and the variables' interactions. Supplemental Figure 6 shows the average simulated survival time by stage and age in the base case scenario (OncoSim v3.3.3).



Supplemental Figure 6. Projected average survival time (years) by age and stage at diagnosis

Supplemental Appendix 6: Breast cancer healthcare costs

Healthcare costs associated with breast cancer were estimated from the perspective of the public healthcare payer, e.g. Ministry of Health. The model estimates lifetime costs of breast cancer by phase of care.

First 18 months: Costs for the first 18 months after diagnosis or cancer recurrence (“acute treatment costs”) were specific to breast cancer treatments. The costs were estimated from a retrospective analysis of healthcare administrative data at the Institute for Clinical Evaluative Sciences (ICES): cancer registry (Cancer Care Ontario), hospitalizations (inpatient, day surgery), physician billings (OHIP), Ontario Drug Benefit program, New Drug Funding Program, and Activity Level Reporting data. The analyses included 11,164 women diagnosed with invasive breast cancer in 2010 or the first 6 months of 2011 where the following cancer characteristics were known: (i) tumour size, (ii) disease stage (collaborative staging), (iii) estrogen receptor and progesterone receptor status (negative, positive), (iv) HER2 status, and (v) tumour grade. The analysis included costs incurred during the first 18 months after diagnosis: breast cancer surgery, radiation treatment, chemotherapy, hormonal treatments, imaging tests, and oncology physician fees. Costs varied by stage and age at diagnosis, molecular subtypes, and grade. Upon recurrence, patients incur additional treatment costs. Since the treatment cost inputs include many types of costs and are broken down by many subgroups, it is not feasible to show all input tables in this appendix document. Supplemental Figure 7 shows an overview of the retrospective database analysis cohort and the aggregated treatment patterns (surgery, radiation therapy and chemotherapy) by stage and age.

Continuing care: After 18 months, patients incur continuing care costs, which included follow-up care with oncology physicians and primary care physicians, laboratory tests and imaging for surveillance.^{15,16} Probabilities and frequency of follow-up care were estimated using clinical expert opinions; costs were then estimated using OHIP schedule of benefits¹³. The model allows continuing care costs to vary by age group, stage, molecular subtypes, grade, and time after diagnosis. Five years after diagnosis with stages 0-III cancer, we assumed that the continuing care costs would decline to include minimal surveillance physician visits and imaging tests. We made this assumption to avoid over-estimating treatment costs; most patients diagnosed with 0-III breast cancer live for many years after diagnosis, and most costing studies did not have sufficient follow-up time to accurately estimate their long-term healthcare costs.

Terminal care: Those who die from breast cancer costs incur terminal care costs in the last three months. We estimated the end-of-life care costs by conducting additional administrative database analyses, building upon a previously published end-of-life care costing study¹⁷. The costs were estimated from a cohort of 1904 patients diagnosed with breast cancer in 2010-2011 and died from breast cancer before March 31, 2014. In addition to the type of costs included in the acute treatment costs, the costs for terminal care include acute hospitalizations, emergency department visits, home care, long-term care, complex continuing care, and others (mental health, dialysis, rehabilitation and devices).



Supplemental Table 10 shows the projected lifetime costs associated with breast cancer by stage.

ANALYSIS COHORT


11,164
women diagnosed with
breast cancer in 2010-2011



~50%
diagnosed at
age 50-69






<4%
diagnosed at
stage IV




TREATMENT PATTERN

Surgery
Most women had surgery
after diagnosed with stage
I-III breast cancer.



Radiation therapy
was common after stage
I-III diagnosis, especially
in patients <70 years old.





<50

50-69

>70




Chemotherapy
was more common in
younger women.



Top 5 cancer drugs

funded by the New Drug
Funding Program



Trastuzumab

84% of all HER2-positive
patients received trastuzumab.

Supplemental Figure 7. Infographic shows an overview of the retrospective database analysis cohort and the aggregated treatment patterns (surgery, radiation therapy and chemotherapy) by stage and age

Supplemental Table 10. Projected lifetime costs associated with breast cancer by stage at diagnosis (2019 CAD\$), average per case

Breast cancer stage at initial diagnosis	Lifetime costs, per case
DCIS	16,900
Stage IA	26,500
Stage IB	38,200
Stage IIA	34,800
Stage IIB	42,800
Stage III	54,100
Stage IV	82,100
All	36,000

Supplemental Appendix 7: Quality-adjusted life-years

Canadian general population

To calculate quality-adjusted life-years for individuals who do not have a breast cancer diagnosis, the model multiplies each life-year with the age-sex specific utility scores of the Canadian general population (Supplemental Table 11). The utility scores were measured using Health Utilities Index Mark 3 and estimated from over 30 million community-dwelling Canadians (98% of the Canadian population) in the 2013-2014 Canadian Community Health Survey.¹⁶

Supplemental Table 11. Age-sex specific utility weight of the Canadian general population

AGE_GROUP	Female	Male
[min,5[1	1
[5,10[0.95	0.95
[10,15[0.93	0.93
[15,20[0.879	0.892
[20,25[0.89	0.892
[25,30[0.902	0.902
[30,35[0.893	0.899
[35,40[0.89	0.898
[40,45[0.874	0.901
[45,50[0.862	0.873
[50,55[0.842	0.856
[55,60[0.83	0.85
[60,65[0.841	0.842
[65,70[0.837	0.848
[70,75[0.831	0.841
[75,80[0.778	0.809
[80,85[0.736	0.748
[85,90[0.616	0.682
[90,95[0.616	0.682
[95,max]	0.616	0.682

Breast cancer

For individuals diagnosed with breast cancer, the model multiplies the breast cancer-specific utility score (Supplemental Table 12) with the probability of treatment phase, the duration of treatment phase and age-sex specific utility weight of the Canadian general population. The breast cancer-specific utility scores came from a utility study that derived utility scores by classifying the impact of a health state across eleven attributes (each with four to five levels) using the CLAssification and MEasurement System of Functional Health (CLAMES).¹⁷ To use the scores from that study, we made the following assumptions:

- We considered DCIS and breast cancer stages I, II, and III as cancers with very good prognosis, and breast cancer stage IV as metastatic cancer (utility score: 0.439).
- When individuals are receiving acute or continuing care, we assumed the utility scores are multiplicative.¹⁸ For example, the health state utility of an individual diagnosed with

stage IV cancer receiving chemotherapy = utility of metastatic cancer * utility of chemotherapy moderate toxicity

Supplemental Table 12. Breast cancer-specific preference score¹⁹

Treatment phase	Preference score
Stage I-III breast cancer	
Diagnosis	0.891
Surgery and immediate follow-up	0.652
Radiotherapy	0.696
Chemotherapy	0.661
Anti-HER2 neu treatment	0.668
Hormonal therapy	0.798
No active treatment	0.906
Stage IV breast cancer	
Diagnosis	0.439
Surgery and immediate follow-up	0.321
Radiotherapy	0.343
Chemotherapy	0.326
Anti-HER2 neu treatment	0.329
No active treatment	0.484
Terminal care	0.179

Supplemental Appendix 8: OncoSim-Breast Working Group

- Anthony Miller (Lead)
- Keiko Asakawa
- John Bartlett
- Andrew Coldman
- Craig Earle
- Beverley Essue
- Natalie Fitzgerald
- William Flanagan
- Rochelle Garner
- Nicolas Irragorri
- Saima Memon
- Nicole Mittmann
- Claude Nadeau
- Michael Wolfson
- Jean Hai Ein Yong
- Tallal Younis

References

1. Miller AB, Baines CJ, To T, Wall C. Canadian National Breast Screening Study: 1. Breast cancer detection and death rates among women aged 40 to 49 years. *CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne* 1992; 147(10): 1459-76.
2. Singletary SE. Rating the risk factors for breast cancer. *Annals of surgery* 2003; 237(4): 474.
3. Chlebowski RT, Rohan TE, Manson JE, et al. Breast cancer after use of estrogen plus progestin and estrogen alone: analyses of data from 2 women's health initiative randomized clinical trials. *JAMA oncology* 2015; 1(3): 296-305.
4. Alagoz O, Ergun MA, Cevik M, et al. The University of Wisconsin Breast Cancer Epidemiology Simulation Model: An Update. *Med Decis Making* 2018; 38(1_suppl): 99s-111s.
5. Kerlikowske K. Epidemiology of ductal carcinoma in situ. *Journal of the National Cancer Institute Monographs* 2010; 2010(41): 139-41.
6. To T, Wall C, Baines CJ, Miller AB. Is carcinoma in situ a precursor lesion of invasive breast cancer? *International journal of cancer* 2014; 135(7): 1646-52.
7. Nekhlyudov L, Habel LA, Achacoso N, et al. Ten-year risk of diagnostic mammograms and invasive breast procedures after breast-conserving surgery for DCIS. *Journal of the National Cancer Institute* 2012; 104(8): 614-21.
8. Tuttle TM, Jarosek S, Habermann EB, et al. Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. *Journal of clinical Oncology* 2009; 27(9): 1362-7.
9. Mavaddat N, Barrowdale D, Andrulis I, et al. HEBON; EMBRACE; GEMO Study Collaborators; kConFab Investigators; SWE-BRCA Collaborators; Consortium of Investigators of Modifiers of BRCA1/2. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). *Cancer Epidemiol Biomarkers Prev* 2012; 21(1): 134-47.
10. Borgquist S, Anagnostaki L, Jirstrom K, Landberg G, Manjer J. Breast tumours following combined hormone replacement therapy express favourable prognostic factors. *International journal of cancer* 2007; 120(10): 2202-7.
11. Coldman AJ, Phillips N. False-positive Screening Mammograms and Biopsies Among Women Participating in a Canadian Provincial Breast Screening Program. *Canadian Journal of Public Health* 2012; 103(6): e420-e4.
12. Carney PA, Miglioretti DL, Yankaskas BC, Kerlikowske K, Rosenberg R, Rutter CM, Geller BM, Abraham LA, Taplin SH, Dignan M, Cutter G, Ballard-Barbash R. 2003. Individual and Combined Effects of Age, Breast Density, and Hormone Replacement Therapy Use on the Accuracy of Screening Mammography. *Annals of Internal Medicine*, 138(3):168-175.
13. Ontario Ministry of Health and Long-Term Care. Ontario Health Insurance Plan Schedule of Benefits and Fees.
14. Cancer Care Ontario. Ontario Breast Screening Program 2011 Report. Toronto, Canada, 2013.
15. Cheung MC, Earle CC, Rangrej J, et al. Impact of aggressive management and palliative care on cancer costs in the final month of life. *Cancer* 2015; 121(18): 3307-15.
16. Guertin JR, Feeny D, Tarride J-E. Age-and sex-specific Canadian utility norms, based on the 2013–2014 Canadian Community Health Survey. *Cmaj*. 2018;190:E155-E61.
17. Boswell-Purdy J, Flanagan WM, Roberge H, Le Petit C, White KJ, Berthelot J-M. Population health impact of cancer in Canada, 2001. *Chronic Diseases and Injuries in Canada*. 2007;28.

18. Flanagan WM, McIntosh CN, Le Petit C, Berthelot J-M. Deriving utility scores for co-morbid conditions: a test of the multiplicative model for combining individual condition scores. *Population Health Metrics* 2006; 4:13.